Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Bafna Pharmaceuticals Ltd - 532989 - Board Meeting Outcome for Outcome Of Board Meeting Held On 16Th Sep 2021

 The Board of Directors of the Company at their meeting held on today i.e 16th September 2021 inter-alia transacted the following business.:- 1. Availing of working capital / Term Loan facility upto Rupees Thirty Crores from ICICI Bank. 2. Opening of Cash Credit Account with ICICI bank. for expansion program. The Board Meeting commenced at 11.00 A.M and concluded at 12.00 Noon.
16-09-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Proposal Of Availing Working Capital / Term Loan Facility For Expansion Program

 BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/09/2021 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday, 16th Sep 2021 online through video conferencing, to inter alia consider the proposal of availing working capital / term loan facility for expansion program and any other business with the permission of the Chair
15-09-2021
Bigul

Bafna Pharmaceuticals Ltd - 532989 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 02, 2021 for Mahveer Chand Bafna, Mahaveer Chand Bafna HUF, Sasikala Bafna, Amribai Bafna and Paras Bafna
02-09-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Bafna Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
16-08-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

 Sub.:- Voting Results and scrutinizer report for the 26th AGM held on 14th August 2021 Ref.:- Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Please find attached voting results for the 26th AGM held on 14th August 2021 under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and scrutinizer report. Please take it in record.
16-08-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Meeting Updates

 Please be informed that the 26th AGM of the Company was held on 14th August 2021 through Video Conferencing ('VC')/ Other Audio Visual Means ('OAVM') at 11.00 a.m. IST. In this regard please find attached the summary of the proceedings of the AGM of the Company. The voting results of the 26th Annual General Meeting of the Company along with the Scrutinizer report will be shared shortly. The 26th Annual General Meeting of the Company was concluded at 12.00 Noon IST We request you to take the above information on your record
14-08-2021

Bafna Pharma Standalone June 2021 Net Sales at Rs 21.26 crore, up 27.28% Y-o-Y

 NULL
05-08-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Q1 2021-22 Results

 The Board of Directors of the Company at their meeting held on today inter-alia transacted the following business.:- 1. UN-AUDITED FINANCIAL RESULT Approval of un-audited financial results of the Company for the quarter ending 30th June 2021. Please find attached Limited Review Report from the statutory auditor of the Company M/s. R. Sathyanarayanan & Co.
05-08-2021
Bigul

Bafna Pharmaceuticals Ltd - 532989 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Bafna Pharma Posts INR 208.70 Lakhs Profit in Q1 Company posts good profits on the back of some great export deliveries. Pandemic has brought the team even closer. Chennai, August 5, 2021: Chennai based Bafna Pharmaceuticals Limited posted a topline growth of Rs. 2142.87 Lakhs, a growth of over 26% in the First Quarter of FY 2021 - 2022 against Rs. 1687.80 Lakhs in the corresponding period last year. The profits for the period surged to Rs. 208.70 Lakhs as against Rs. 181.16 Lakhs last year; registering a robust growth of 15%. Bafna Pharma has been listed in BSE and NSE. This robust growth has come despite the raging pandemic for most part of the quarter. Says Head of Business Development, Navin Bafna, 'this growth in numbers has been due to the collective efforts of the team who worked incredibly hard to achieve it inspite of the uncertainty and personal losses. Our business model and the government's vision of giving priority to Pharma products' exports.
05-08-2021
Bigul

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 05Th August 2021

 The Board of Directors of the Company at their meeting held on today inter-alia transacted the following business.:- 1. UN-AUDITED FINANCIAL RESULT Approval of un-audited financial results of the Company for the quarter ending 30th June 2021. Please find attached Limited Review Report from the statutory auditor of the Company M/s. R. Sathyanarayanan & Co.
05-08-2021
Next Page
Close

Let's Open Free Demat Account